Quarterly report pursuant to Section 13 or 15(d)

INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative)

v3.20.1
INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 12, 2018
Aug. 20, 2018
Mar. 31, 2020
Dec. 31, 2019
Amortization expense $ 292   $ 11,790  
Estimated useful lives 13 years     5 years
Accumulated amortization     $ 23,780 $ 11,990
Patents $ 1,755    
Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member]        
cash paid for acquisition   $ 10,000    
Aggregate purchase price, Shares   20,000    
Aggregate purchase price, value   $ 236,000    
Patent acquired $ 15,200